Nitazoxanide Versus Placebo for the Treatment of Hospitalized Subjects With Severe Acute Respiratory Illness

PHASE2CompletedINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

May 31, 2017

Study Completion Date

January 31, 2018

Conditions
Severe Acute Respiratory Illness
Interventions
DRUG

Nitazoxanide

"Participants 1 to 3 years old: 5 mL oral suspension (100 mg NTZ) every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL oral suspension (200 mg NTZ) every 12 hours for 5 days.~Participants 12 years and older: two 300-mg NTZ tablets orally twice daily for 5 days."

DRUG

Placebo

"Participants 1 to 3 years old: 5 mL placebo oral suspension every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL placebo oral suspension every 12 hours for 5 days.~Participants 12 years and older: two placebo tablets orally twice daily for 5 days."

Trial Locations (6)

14000

Instituto Nacional de Ciencias medicas y Nutricion Salvador Zubiran, Tlalpan

Instituto Nacional de Enfermedades Respiratorias, Tlalpan

68050

Hospital General Dr. Aurelio Valdivieso, Oaxaca City

78240

Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosí City

04530

Instituto Nacional de Pediatria, Coyoacán

06720

Hospital Infantil de Mexico Federico Gomez, Tamaulipas

All Listed Sponsors
collaborator

Mexican Emerging Infectious Diseases Clinical Research Network

NETWORK

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02057757 - Nitazoxanide Versus Placebo for the Treatment of Hospitalized Subjects With Severe Acute Respiratory Illness | Biotech Hunter | Biotech Hunter